Blackstone Medical competitors

Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

A co-founder of CBLPath via the CBL acquisition, Carlos Urmacher is certified by the American Board of Pathology in Surgical Pathology and Dermatopathology. He is a member of the U.S. and Canadian Academy of Pathology, a member of the College of American Pathologists, and a fellow of the American Society of Clinical Pathologists. Dr. Urmacher has served as a member of the Board of Trustees and Treasurer of the New York Pathological Society, as a member of the Scientific Advisory Board of the World Health Organization and as a member of the editorial boards of The American Journal of Surgical Pathology and The American Journal of Dermatopathology. Prior to joining CBL in 2000 as Co-Director and Chief of Surgical Pathology, Dr. Urmacher served as Attending Pathologist at North Shore University Hospital – NYU School of Medicine in Manhasset, New York for nine years and as Attending Pathologist at Memorial Sloan-Kettering Cancer Center and Associate Professor of Pathology at Cornell University Medical Center for 13 years. Dr. Urmacher is a frequent lecturer and has authored more than 70 articles and six medical textbook chapters. He graduated with an M.D. degree from the Central University of Venezuela and served as Chief Resident in Pathology at Mount Sinai Hospital, New York and as Chief Fellow in Pathology at Memorial Sloan-Kettering Cancer Center and New York University Hospital. Dr. Urmacher was recently giving the honor of distinguished visitor professor in Pathology by Johns Hopkins.